Sling Therapeutics Raises $123 Million Series C to Advance Thyroid Eye Disease Therapy

Sling Therapeutics has raised $123 million in Series C funding, the company announced September 16, 2026, in a round backed by Forbion, TPG Life Sciences Innovations and Sectoral Asset Management. The company will use the capital to advance linsitinib, an oral therapy it is developing for thyroid eye disease, a serious and often debilitating autoimmune condition that causes inflammation and swelling around the eyes and can, in severe cases, threaten vision. The round adds Sling Therapeutics to a cluster of well-capitalised biotech companies that closed substantial financing rounds this week, reflecting continued investor confidence in differentiated therapeutic programmes addressing conditions with significant unmet medical need.

Thyroid eye disease, also known as Graves' orbitopathy, is most commonly associated with Graves' disease, an autoimmune disorder that affects thyroid function, though the eye condition itself involves a distinct autoimmune process that can persist even after underlying thyroid hormone levels have been brought under control through conventional treatment. Patients with more severe forms of the condition can experience significant physical discomfort, visible disfigurement and, in serious cases, compressive optic neuropathy that threatens permanent vision loss, making effective treatment options a meaningful area of unmet clinical need within ophthalmology and endocrinology.

The therapeutic category has attracted growing pharmaceutical and biotech investment attention since the approval of the first targeted biologic therapy specifically for thyroid eye disease several years ago, which validated the condition as a viable target for dedicated drug development and demonstrated meaningful commercial potential for effective treatments. That approval reshaped how patients and physicians think about thyroid eye disease treatment, moving the condition from one managed primarily through supportive care and, in severe cases, surgical intervention, toward one where targeted pharmacological therapy has become a genuine first-line consideration. Sling Therapeutics' oral candidate represents part of a broader wave of follow-on drug development attempting to build on that initial validation, with an oral administration route offering a potential convenience advantage over infused biologic therapies that require regular clinical visits for administration.

The involvement of Forbion and TPG Life Sciences Innovations as lead investors brings considerable specialist biotech investing experience to Sling Therapeutics' cap table. Forbion, a European life-sciences investor with a long track record backing clinical-stage biopharmaceutical companies, has built a reputation for disciplined, science-driven investment decisions across multiple therapeutic areas, while TPG Life Sciences Innovations represents the life-sciences arm of one of the world's largest alternative asset managers, bringing both capital depth and broader healthcare-sector relationships that can prove valuable as clinical-stage companies navigate the complex path toward regulatory approval and eventual commercialisation.

For Sling Therapeutics, the Series C capital is likely to fund continued clinical development of linsitinib, advancing the oral candidate through the trial stages necessary to generate the safety and efficacy data regulators will require before considering approval. Oral small-molecule therapies in autoimmune and inflammatory disease categories face a well-established regulatory and clinical development pathway, though the company will still need to demonstrate that linsitinib's efficacy profile compares favourably against existing treatment options, including the biologic therapy that first validated the category, in order to secure meaningful commercial uptake even if the drug ultimately gains regulatory approval.

The broader competitive landscape in thyroid eye disease treatment is likely to intensify over the coming years as multiple biopharmaceutical companies pursue both biologic and small-molecule approaches to the condition, drawn by the combination of validated commercial demand and continued unmet need among patients who do not respond adequately to existing therapies or who prefer the convenience of oral administration over infused treatments. Sling Therapeutics' substantial Series C round gives the company meaningful runway to advance its clinical programme, but the ultimate measure of the investment's success will rest on whether linsitinib can generate clinical trial data compelling enough to differentiate it within an increasingly competitive therapeutic category.

The Series C round also highlights how specialist biotech investors increasingly view rare and orphan-adjacent autoimmune conditions as an attractive category for differentiated drug development, even though thyroid eye disease affects a comparatively small patient population relative to more common chronic diseases. Conditions with a well-defined patient population, a validated biological mechanism and a demonstrated willingness among payers to reimburse effective therapies — all established following the earlier approval of the category's first targeted biologic — offer biotech investors a more predictable commercial pathway than pursuing entirely novel disease targets without prior regulatory or reimbursement precedent. Sling Therapeutics' decision to pursue an oral small-molecule approach within an already-validated therapeutic category reflects a calculated strategy: rather than bearing the full risk of proving a new biological target, the company is instead betting that a more convenient route of administration can capture meaningful market share from patients and physicians seeking alternatives to existing infused biologic treatments, a strategy that, if successful, could meaningfully expand the overall addressable market for thyroid eye disease therapies beyond patients willing to undergo regular infusions.

Investors in this round will also be tracking how quickly Sling Therapeutics can generate comparative clinical data against the existing approved biologic therapy for thyroid eye disease, since payers and physicians will ultimately need to be convinced that an oral alternative offers a genuinely compelling trade-off in efficacy, safety and convenience rather than simply a different route of administration. Positive late-stage trial results demonstrating meaningful symptom improvement, particularly in patients who have not responded adequately to existing treatments, would significantly strengthen the commercial case for linsitinib and could position Sling Therapeutics for a substantial follow-on financing round or strategic partnership as it approaches potential regulatory filing.

Sling Therapeutics' progress will also be closely watched by investors in adjacent autoimmune and ophthalmology-focused biotech companies, given that a successful oral therapy approval could reshape treatment paradigms and referral pathways across a broader set of inflammatory eye conditions beyond thyroid eye disease specifically.

For now, the $123 million round buys Sling Therapeutics the runway and investor patience needed to let its clinical programme speak for itself over the coming trial readouts.

Whichever way the trial data ultimately breaks, the round confirms that specialist biotech investors still see meaningful room for differentiated approaches within an already-validated disease category.